1. Home
  2. IART vs REPL Comparison

IART vs REPL Comparison

Compare IART & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra LifeSciences Holdings Corporation

IART

Integra LifeSciences Holdings Corporation

HOLD

Current Price

$10.04

Market Cap

823.8M

Sector

Health Care

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$2.40

Market Cap

692.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IART
REPL
Founded
1989
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
823.8M
692.8M
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
IART
REPL
Price
$10.04
$2.40
Analyst Decision
Hold
Hold
Analyst Count
7
9
Target Price
$14.33
$5.67
AVG Volume (30 Days)
689.1K
9.8M
Earning Date
05-05-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.25
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.39
N/A
Revenue Next Year
$3.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.70
$1.50
52 Week High
$17.04
$13.24

Technical Indicators

Market Signals
Indicator
IART
REPL
Relative Strength Index (RSI) 47.18 33.50
Support Level $8.79 $1.50
Resistance Level $11.57 $8.83
Average True Range (ATR) 0.56 0.45
MACD -0.01 0.04
Stochastic Oscillator 22.19 17.96

Price Performance

Historical Comparison
IART
REPL

About IART Integra LifeSciences Holdings Corporation

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: